Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Orion Corp.

Headquarters: Espoo, Finland
Year Founded: 1917
Status: Public
Industry Sector: HealthTechnology
CEO: Aino Anna Liisa Hurme, PhD
Number Of Employees: 3,712
Enterprise Value: $6,363,798,108
PE Ratio: 23.33
Exchange/Ticker 1: HSE:ORNAV
Exchange/Ticker 2: HSE:ORNBV
Latest Market Cap: $8,343,859,042

BioCentury | Oct 1, 2024
Deals

Prime narrows gene editing focus with BMS deal

Deals Report: Novartis-Generate use AI to develop protein therapies, and updates from Roche-Regor, CSPC-Alphamab and more
BioCentury | May 7, 2024
Management Tracks

Seaport rounds out C-suite with new hires

Plus: Germany-based Topas taps new CEO, and updates from Quest, Nimbus and more
BioCentury | Jan 25, 2024
Management Tracks

Moeller named CEO of BenevolentAI

Plus: new CFO at Orion and updates from Alkeus and Immorta
BioCentury | Jan 19, 2024
Finance

Public equity roundup: Edgewise shares get lift after $240M offering

Plus offerings by Immatics, Viridion, Alector, LegoChem and more
BioCentury | Mar 23, 2023
Management Tracks

Treco to succeed Bolte as CEO of Inozyme

Plus: Seagen’s Siegall to be CEO at Morphimmune and updates from Jasper, Vividion and more
BioCentury | Nov 29, 2022
Regulation

Nov. 28 Quick Takes: Priority review for Sarepta’s DMD gene therapy

Plus: Science reports second lecanemab death and updates from AZ, C4X, Spectrum, Strand, CinCor and more
BioCentury | Oct 19, 2022
Management Tracks

New chairs at SomaLogic, Anjarium

Plus Dechamps becomes CEO at Bioxodes, and updates from Abalos, M2Gen and Orion
BioCentury | Sep 21, 2022
Management Tracks

New CEOs at Scholar Rock, Neuway, NeuVasQ and ProLynx

Plus Serono’s Maria Rivas joins Pfizer, and updates from 
BioCentury | Aug 19, 2022
Deals

Deal for Jemincare PROTAC signals Roche’s aim to expand dealmaking in China

Genentech paying Shanghai biotech $60 million up front for global rights to androgen receptor degrader
BioCentury | Aug 9, 2022
Politics, Policy & Law

Aug. 8 Quick Takes: Insulin cap, carried interest out, drug pricing regulation in

Plus cash crunch for Clovis, tumble for Novavax, clinical updates from CinCor, Reata, Hutchmed, Kodiak and more
Items per page:
1 - 10 of 185